Common Side Effects of Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, most often causes upper respiratory infections, diarrhea, and nasopharyngitis in the first few months. These typically resolve without stopping treatment.[1]
Reported Long-Term Side Effects
Clinical trials and post-marketing data show infections remain the primary concern over years of use. In a 5-year psoriasis study, serious infections occurred in 1.3% of patients annually, including tuberculosis reactivation in those with latent exposure. Inflammatory bowel disease (IBD) flares, like Crohn's disease, emerged in 0.6-1.1% of cases, sometimes leading to discontinuation. Rare cases include neutropenia and hypersensitivity reactions persisting beyond initial dosing.[2][3]
Risks Over 5+ Years of Use
Longer-term registries (e.g., 10-year data from European psoriasis cohorts) report stable infection rates but highlight malignancy risks: non-melanoma skin cancers slightly elevated (standardized incidence ratio 1.2-1.5), though not consistently linked to Cosentyx alone. No strong signal for solid tumors or lymphoma compared to other biologics. IBD risk appears highest in the first 1-2 years but persists.[4]
What Happens If You Develop IBD on Cosentyx?
Cosentyx carries a boxed warning for new-onset or worsening IBD. Patients with a history should avoid it. Symptoms like abdominal pain or bloody stools require immediate specialist review; about 20% of affected patients in trials needed hospitalization.[2]
How Does Long-Term Safety Compare to Other Biologics?
Versus TNF inhibitors like Humira, Cosentyx has lower serious infection rates (OR 0.7 in meta-analyses) but higher IBD risk (RR 2.5). Against IL-23 inhibitors like Tremfya, infection profiles are similar, with fewer injection-site reactions long-term.[5]
Monitoring and Patient Concerns
Annual TB screening, blood counts, and IBD symptom checks are standard. Patients report fatigue and mild URI persistence in forums, but registries show 80-90% continue therapy beyond 3 years without major issues. No pediatric long-term data exceeds 2 years.[3]
[1]: Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com
[2]: FDA Label, Secukinumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s whatever.pdf
[3]: EADV Psoriasis Registry, 5-year data. https://www.eadv.org
[4]: British Journal of Dermatology, 2022 long-term safety review. https://academic.oup.com/bjd/article/187/3/345/
[5]: Lancet Rheumatology meta-analysis, 2021. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00045-2/fulltext